Shell Companies
Compare Stocks
5 / 10Stock Comparison
AFJK vs ACMR vs ICHR vs CANG vs MKSI
Revenue, margins, valuation, and 5-year total return — side by side.
Semiconductors
Semiconductors
Auto - Dealerships
Hardware, Equipment & Parts
AFJK vs ACMR vs ICHR vs CANG vs MKSI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Shell Companies | Semiconductors | Semiconductors | Auto - Dealerships | Hardware, Equipment & Parts |
| Market Cap | $261M | $3.92B | $2.47B | $250M | $20.25B |
| Revenue (TTM) | $0.00 | $901M | $959M | $3.46B | $4.07B |
| Net Income (TTM) | $1M | $94M | $-51M | $-178M | $327M |
| Gross Margin | — | 44.4% | 11.3% | 13.6% | 45.2% |
| Operating Margin | — | 12.1% | -3.8% | 7.3% | 14.8% |
| Forward P/E | 251.0x | 30.8x | 62.2x | 5.7x | 27.3x |
| Total Debt | $2M | $303M | $186M | $170M | $4.69B |
| Cash & Equiv. | $3K | $766M | $98M | $1.29B | $675M |
AFJK vs ACMR vs ICHR vs CANG vs MKSI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jan 24 | May 26 | Return |
|---|---|---|---|
| Aimei Health Techno… (AFJK) | 100 | 419.2 | +319.2% |
| ACM Research, Inc. (ACMR) | 100 | 347.6 | +247.6% |
| Ichor Holdings, Ltd. (ICHR) | 100 | 205.6 | +105.6% |
| Cango Inc. (CANG) | 100 | 109.7 | +9.7% |
| MKS Inc. (MKSI) | 100 | 294.2 | +194.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AFJK vs ACMR vs ICHR vs CANG vs MKSI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AFJK is the #2 pick in this set and the best alternative if stability is your priority.
- Beta 0.23 vs ICHR's 3.93, lower leverage
ACMR carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 15.2%, EPS growth -10.5%, 3Y rev CAGR 32.3%
- 30.7% 10Y total return vs MKSI's 7.5%
- 15.2% revenue growth vs AFJK's -57.2%
- 10.4% margin vs ICHR's -5.3%
ICHR ranks third and is worth considering specifically for momentum.
- +329.1% vs CANG's -73.7%
CANG is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 2.25, Low D/E 4.1%, current ratio 1.88x
- Lower P/E (5.7x vs 27.3x)
MKSI is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 0 yrs, beta 2.64, yield 0.3%
- Beta 2.64, yield 0.3%, current ratio 2.71x
- 0.3% yield, vs ACMR's 0.2%, (3 stocks pay no dividend)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 15.2% revenue growth vs AFJK's -57.2% | |
| Value | Lower P/E (5.7x vs 27.3x) | |
| Quality / Margins | 10.4% margin vs ICHR's -5.3% | |
| Stability / Safety | Beta 0.23 vs ICHR's 3.93, lower leverage | |
| Dividends | 0.3% yield, vs ACMR's 0.2%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +329.1% vs CANG's -73.7% | |
| Efficiency (ROA) | 3.9% ROA vs ICHR's -5.2%, ROIC 7.0% vs -3.9% |
AFJK vs ACMR vs ICHR vs CANG vs MKSI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
AFJK vs ACMR vs ICHR vs CANG vs MKSI — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MKSI leads in 1 of 6 categories
CANG leads 1 • ACMR leads 1 • AFJK leads 0 • ICHR leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
MKSI leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MKSI and AFJK operate at a comparable scale, with $4.1B and $0 in trailing revenue. ACMR is the more profitable business, keeping 10.4% of every revenue dollar as net income compared to ICHR's -5.3%. On growth, CANG holds the edge at +58.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $901M | $959M | $3.5B | $4.1B |
| EBITDAEarnings before interest/tax | -$835,759 | $126M | -$11M | $333M | $945M |
| Net IncomeAfter-tax profit | $1M | $94M | -$51M | -$178M | $327M |
| Free Cash FlowCash after capex | -$565,100 | -$69M | -$17M | $0 | $401M |
| Gross MarginGross profit ÷ Revenue | — | +44.4% | +11.3% | +13.6% | +45.2% |
| Operating MarginEBIT ÷ Revenue | — | +12.1% | -3.8% | +7.3% | +14.8% |
| Net MarginNet income ÷ Revenue | — | +10.4% | -5.3% | -5.2% | +8.0% |
| FCF MarginFCF ÷ Revenue | — | -7.6% | -1.7% | -154.0% | +9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +9.4% | +4.7% | +58.3% | +15.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -59.1% | -76.1% | +46.2% | +3.6% | +53.2% |
Valuation Metrics
CANG leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
At 5.7x trailing earnings, CANG trades at a 98% valuation discount to AFJK's 251.0x P/E. On an enterprise value basis, CANG's 3.1x EV/EBITDA is more attractive than ACMR's 27.5x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $261M | $3.9B | $2.5B | $250M | $20.2B |
| Enterprise ValueMkt cap + debt − cash | $263M | $3.5B | $2.6B | $85M | $24.3B |
| Trailing P/EPrice ÷ TTM EPS | 251.03x | 43.21x | -46.25x | 5.66x | 68.83x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 30.81x | 62.25x | — | 27.27x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.22x | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 27.49x | — | 3.13x | 26.70x |
| Price / SalesMarket cap ÷ Revenue | — | 4.35x | 2.61x | 2.12x | 5.15x |
| Price / BookPrice ÷ Book value/share | 21.48x | 2.06x | 3.67x | 0.42x | 7.49x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 40.74x |
Profitability & Efficiency
Evenly matched — ACMR and MKSI each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
MKSI delivers a 12.2% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-8 for ICHR. CANG carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to MKSI's 1.73x. On the Piotroski fundamental quality scale (0–9), MKSI scores 6/9 vs ACMR's 2/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +3.2% | +6.1% | -7.5% | -4.1% | +12.2% |
| ROA (TTM)Return on assets | +2.9% | +3.9% | -5.2% | -2.3% | +3.7% |
| ROICReturn on invested capital | -1.5% | +7.0% | -3.9% | +4.6% | +6.5% |
| ROCEReturn on capital employed | -2.0% | +6.6% | -4.7% | +4.5% | +7.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 | 3 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.25x | 0.16x | 0.28x | 0.04x | 1.73x |
| Net DebtTotal debt minus cash | $2M | -$463M | $87M | -$1.1B | $4.0B |
| Cash & Equiv.Liquid assets | $2,929 | $766M | $98M | $1.3B | $675M |
| Total DebtShort + long-term debt | $2M | $303M | $186M | $170M | $4.7B |
| Interest CoverageEBIT ÷ Interest expense | — | 20.44x | -5.97x | -1.87x | 2.84x |
Total Returns (Dividends Reinvested)
ACMR leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AFJK five years ago would be worth $42,044 today (with dividends reinvested), compared to $8,579 for CANG. Over the past 12 months, ICHR leads with a +329.1% total return vs CANG's -73.7%. The 3-year compound annual growth rate (CAGR) favors ACMR at 80.5% vs CANG's 0.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -43.7% | +31.9% | +249.0% | -62.0% | +78.8% |
| 1-Year ReturnPast 12 months | +288.0% | +195.6% | +329.1% | -73.7% | +306.1% |
| 3-Year ReturnCumulative with dividends | +320.4% | +487.9% | +151.1% | +1.2% | +266.0% |
| 5-Year ReturnCumulative with dividends | +320.4% | +133.4% | +28.9% | -14.2% | +66.5% |
| 10-Year ReturnCumulative with dividends | +320.4% | +3065.8% | +629.1% | -44.9% | +750.6% |
| CAGR (3Y)Annualised 3-year return | +61.4% | +80.5% | +35.9% | +0.4% | +54.1% |
Risk & Volatility
Evenly matched — AFJK and ICHR each lead in 1 of 2 comparable metrics.
Risk & Volatility
AFJK is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than ICHR's 3.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ICHR currently trades 97.7% from its 52-week high vs CANG's 18.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.32x | 3.17x | 3.78x | 2.49x | 2.56x |
| 52-Week HighHighest price in past year | $130.37 | $71.65 | $72.87 | $2.88 | $326.83 |
| 52-Week LowLowest price in past year | $6.75 | $19.26 | $13.12 | $0.33 | $71.49 |
| % of 52W HighCurrent price vs 52-week peak | +32.7% | +82.6% | +97.7% | +18.6% | +92.0% |
| RSI (14)Momentum oscillator 0–100 | 54.2 | 60.7 | 66.9 | 58.6 | 65.3 |
| Avg Volume (50D)Average daily shares traded | 21K | 1.2M | 795K | 1.3M | 1.2M |
Analyst Outlook
Evenly matched — CANG and MKSI each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ACMR as "Buy", ICHR as "Buy", CANG as "Buy", MKSI as "Buy". Consensus price targets imply 459.2% upside for CANG (target: $3) vs -30.1% for ICHR (target: $50). For income investors, MKSI offers the higher dividend yield at 0.29% vs ACMR's 0.19%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $75.00 | $49.80 | $3.00 | $294.25 |
| # AnalystsCovering analysts | — | 10 | 14 | 2 | 29 |
| Dividend YieldAnnual dividend ÷ price | — | +0.2% | — | — | +0.3% |
| Dividend StreakConsecutive years of raises | — | 3 | 1 | 5 | 0 |
| Dividend / ShareAnnual DPS | — | $0.11 | — | — | $0.87 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.2% | 0.0% | +5.3% | +0.2% |
MKSI leads in 1 of 6 categories (Income & Cash Flow). CANG leads in 1 (Valuation Metrics). 3 tied.
AFJK vs ACMR vs ICHR vs CANG vs MKSI: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AFJK or ACMR or ICHR or CANG or MKSI a better buy right now?
For growth investors, ACM Research, Inc.
(ACMR) is the stronger pick with 15. 2% revenue growth year-over-year, versus -52. 7% for Cango Inc. (CANG). Cango Inc. (CANG) offers the better valuation at 5. 7x trailing P/E, making it the more compelling value choice. Analysts rate ACM Research, Inc. (ACMR) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AFJK or ACMR or ICHR or CANG or MKSI?
On trailing P/E, Cango Inc.
(CANG) is the cheapest at 5. 7x versus Aimei Health Technology Co. , Ltd at 251. 0x. On forward P/E, MKS Inc. is actually cheaper at 27. 3x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — AFJK or ACMR or ICHR or CANG or MKSI?
Over the past 5 years, Aimei Health Technology Co.
, Ltd (AFJK) delivered a total return of +320. 4%, compared to -14. 2% for Cango Inc. (CANG). Over 10 years, the gap is even starker: ACMR returned +31. 0% versus CANG's -43. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AFJK or ACMR or ICHR or CANG or MKSI?
By beta (market sensitivity over 5 years), Aimei Health Technology Co.
, Ltd (AFJK) is the lower-risk stock at 0. 32β versus Ichor Holdings, Ltd. 's 3. 78β — meaning ICHR is approximately 1077% more volatile than AFJK relative to the S&P 500. On balance sheet safety, Cango Inc. (CANG) carries a lower debt/equity ratio of 4% versus 173% for MKS Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — AFJK or ACMR or ICHR or CANG or MKSI?
By revenue growth (latest reported year), ACM Research, Inc.
(ACMR) is pulling ahead at 15. 2% versus -52. 7% for Cango Inc. (CANG). On earnings-per-share growth, the picture is similar: Cango Inc. grew EPS 960. 0% year-over-year, compared to -140. 6% for Ichor Holdings, Ltd.. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AFJK or ACMR or ICHR or CANG or MKSI?
Cango Inc.
(CANG) is the more profitable company, earning 37. 3% net margin versus -5. 6% for Ichor Holdings, Ltd. — meaning it keeps 37. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CANG leads at 22. 2% versus -4. 1% for ICHR. At the gross margin level — before operating expenses — CANG leads at 55. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AFJK or ACMR or ICHR or CANG or MKSI more undervalued right now?
On forward earnings alone, MKS Inc.
(MKSI) trades at 27. 3x forward P/E versus 62. 2x for Ichor Holdings, Ltd. — 35. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CANG: 459. 2% to $3. 00.
08Which pays a better dividend — AFJK or ACMR or ICHR or CANG or MKSI?
In this comparison, MKSI (0.
3% yield), ACMR (0. 2% yield) pay a dividend. AFJK, ICHR, CANG do not pay a meaningful dividend and should not be held primarily for income.
09Is AFJK or ACMR or ICHR or CANG or MKSI better for a retirement portfolio?
For long-horizon retirement investors, Aimei Health Technology Co.
, Ltd (AFJK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 32), +320. 4% 10Y return). Cango Inc. (CANG) carries a higher beta of 2. 49 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AFJK: +320. 4%, CANG: -43. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AFJK and ACMR and ICHR and CANG and MKSI?
These companies operate in different sectors (AFJK (Financial Services) and ACMR (Technology) and ICHR (Technology) and CANG (Consumer Cyclical) and MKSI (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: AFJK is a small-cap quality compounder stock; ACMR is a small-cap high-growth stock; ICHR is a small-cap quality compounder stock; CANG is a small-cap deep-value stock; MKSI is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.